Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I may be a babe in the woods regarding option strategies, but do know the entity would have unrealized gains on the trade of $45k, not your figure, if there is a 15ct gain thus far.
its a bet, not a hedge! and I hope it blows up in their face. I'll stick with plain vanilla stock for ownership purpose as my bet , while still pondering MNTA's technological advantages, if they have any?
If it was selling of puts and calls as you say, its not a hedge. If bad news brings MNTA to $7, the fund just bought another 300k
I will agree its a bet that the stock is not going outside the range you specified
how do you know it was not a collar where they sold covered calls against their position and bought a put options to protect on the downside?
based on the option prices which the call and puts traded it is discouraging.
just asking, any chance this has nothing to do with court case and possibly to do with approval process? Could they receive a CRL at this point?
666k shares traded. wonder if after a bear raid on Friday, we are now seeing some devilish short covering. based on call option open interest, does not look like these guys are hedged for possible approval or any good news
While I understand the stock's negative reaction due to more programs and uncertainty in funding of them, did friday's presentation substantiate MNTA's technology as differentiated for those of you with biotech backrounds?
Are management comments regarding MCopaxone, specifically no outstanding questions by the FDA, in line with what Mylan and others are saying?
"We are pleased to receive Orphan Drug Designation for necuparanib, which highlights the great need for new medications for patients suffering from pancreatic cancer," said Jim Roach MD, Chief Medical Officer of Momenta Pharmaceuticals. "We are encouraged by the progress of the program to date, and in the next several months, we anticipate completing Part A of our ongoing Phase 1/2 study of necuparanib in combination with Abraxane® and gemcitabine. We look forward to sharing the results from Part A and advancing the product into the Phase 2 part of the study in the second half of 2014."
was this the hint and will we hear more tomorrow?
How about that GDUFA?
Dew, what would give you that thought process given lack of volume and option activity?
boston based north tide capital initiated a new position of 2.5 mm shares in the last few months. We'll have to see if they are smarter than the increasing short position.
I will pour us all another glass of whine .... oh I mean wine!. Its been very frustrating to be a long term holder of MNTA, coupled with constant litigation uncertainty and FDA approval processes
from an optimistic standpoint, MNTA is outperforming TEVA and MYL in last couple of weeks coupled with lack of insider sales as Dew has pointed out. Is the market trying to tell us something?
http://www.reuters.com/article/2013/07/26/us-teva-copaxone-patent-idUSBRE96P0V520130726
the version I read did not have the "subject to regulatory approval" add on
was she not touting myl would have the approval prior to May 24th before? fact is we are all clueless as to when approval will come. I hope the FDA types working on the ANDA's are less clueless
institutional size options trades on the SEPT 17 calls and 11 puts
Dew, I respect your knowledge base and detail but we still need favorable FDA approval and litigation news to grasp profits from a generic Copaxone.
I asked before and the calendar seemed to determine your response.... but here we are well after May 24th and when do insightful people ask whether GDUFA is really accomplishing the goals intended?
Thanks
games are being played by market makers and hedge funds. I hope some of them get caught offsides. Jokingly, some will their spend a FDA career working on the MNTA/Sandoz ANDA.
technical analysis can be turned on it's head instantaneously by a fundamental announcement. to say this stock has been managed is an understatement IMO.
thanks. sure would be nice to see an approval and minimization of litigation concerns
Dew regarding your rough estimates of MNTA/NVS possibly attaining $420mm of annual Copaxone sales given ANDA approval for MNTA/NVS .... do you assign or have an estimate on margins. If I remember correctly, with NVS this is a 50/50 profit split?
are you trying to say sort of like if a hedge fund such as SAC bought a block of stock after hours yesterday from a market maker and now that market maker is short a good number of shares and now manages the stock in a way to accumulate shares to hedge his position on a day like today.
I am bewildered by the recent growing short interest. Seems to me they have not protected themselves well, based on the open interest of call options and recent options activity. They have brass balls or know something many of us do not IMO
won't be surprising to me if SAC after losing money on the long side, turned around shorted the stock and now are engaging their hyena like hedge fund peers to do the same. Piling on a short position at these prices seems illogical unless there is some sort of news circulating that approval is not coming anytime soon imo
why do you think this patent assignment is so meaningful? will it help the fda speed up the the approval process?
Why would anyone layer on a short position over the last few weeks unless they had confidence an approval is not coming any time soon? Outside of the Forbes article, gene expression and newest CP is there anything that would give an investor reason to short or press a short position?
you see the rise in short interest. Obviously some believe we will not see an approval for some time to come
when does the board debate the merits and limitations of GDUFA? seems like "priority" due to patent expirations is a little off base in this instance.
I'm I naïve to think that TEVA/SYN news today is an incremental plus for MNTA and Mylan.
Yesterday around noon volume and price spiked. as the afternoon progressed I saw large option call option action in the June 13's and 15's. Overall call volume was multiples of put volume. Any thoughts?
and Dew or anyone else... GDUFA seems to be a complete failure in terms of expediting the review process from a generic company standpoint. What can they or investors do to wake congress up on the unintended consequences of the act
as for the frustration on this board. wow there have so many times that frustration has led me to sell a stock at breakeven or small gain and then it just takes off. Hopefully I've learned the lesson.
Question for anyone, especially with a legal backround. How much can we glean from the Nautilus case? Are the two cases that much different? Teva's petition cites the two share a common pivotal question. How long should we expect till a ruling in that case is made?
Like others, seems to me mCopaxone is severely discounted in MNTA's current valuation and that case may provide a potential catalyst?
http://blogs.findlaw.com/federal_circuit/2014/03/nautilus-v-biosig-instruments-scotus-oral-arguments-almost-here.html
sounds to me you in better shape than most because if that's your buying experience. I've been riding the rollercoaster MNTA for the last few years. Patience is a virtue when investing but will drive you crazy if short term gratification is needed.
Worst case scenario in the short term is a NON approval letter for mCopaxone IMO.
uncertainty creates opportunity. buy when there is blood in the streets IMO
"In February, a divided 6-4 court affirmed that
policy in another case, which may have led to the high court
taking this case, said David Long, a patent lawyer with Kelley
Drye in Washington".
Regarding this sentence from the last article, does anyone know what case this lawyer is referring to?
thank you for also answering my question regarding characterization differentiation. This is a very informational board even though the last few years have been frustrating for shareholders
thank you all for this board. Question for anyone? What makes MNTA's characterization process differentiated, as it seems, competitors such as Synthon, Mylan/Natco, Amphastar are always abound?